8-K current report · filed Sep 9, 2026

Xeris Biopharma Holdings, Inc. (XERS) 8-K Current Report: September 9, 2026

Item 7.01XERS overview

Short answer

Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 7.01 (Regulation FD Disclosure). XP-8121 Program Overview webinar scheduled for September 9, 2026.

Xeris Biopharma Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • XP-8121 Program Overview webinar scheduled for September 9, 2026
  • Investor presentation and accompanying press release provide program updates, accessible through Exhibits 99.1 and 99.2
  • Disclosure signals an investor-focused update on XP-8121 development and potential strategic relevance

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Xeris Biopharma Holdings, Inc. 8-K filings

Get the next XERS 8-K as it lands

Follow XERS for push alerts, or ask the research agent what this filing means.